The ratio between CD4 + and CD8 + cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide

References

• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalido-mide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Rajkumar SV, Hanson CA, Schroeder GS, Tefferi, A. Evaluation and clinical correlation of microvessel density in myelofibrosis with myeloid metaplasia. Blood 1999;94\(Suppl. 1):115a.
   Google Scholar
• Singhal S, Metha J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Visani G, Pileri SA et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609–1614.
   PubMed Web of Science ®Google Scholar
• Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16:1–6.
   PubMed Web of Science ®Google Scholar
• Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002;43:133–137.
   Google Scholar
• Kumar S, Witzig TE, Dispenzieri A et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004;18:624–627.
   PubMed Web of Science ®Google Scholar
• Du W, Hattori Y, Hashiguchi A et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int 2004;54:285–294.
   PubMed Web of Science ®Google Scholar
• Liu WM, Strauss SJ, Chaplin T et al. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J 2004;5:247–254.
   PubMedGoogle Scholar
• Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58:107–113.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PAL Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-z. J Immunol 1999;163:380–386.
   Google Scholar
• Hanekom WA, Hughes J, Haslett PA et al. The immunomo-dulatory effects of thalidomide on human immunodeficiency virus-infected children. J Infect Dis 2001;184:1192–1196.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Klausner JD, Makonkawkeyoon S et al. Thalido-mide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retro-viruses 1999;15:1169–1179.
   PubMed Web of Science ®Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med 1998187:1885-1892.
   PubMed Web of Science ®Google Scholar
• McHugh SM, Rifkin JR, Deighton J et al. The immunosup-pressive drug thalidomide induces T helper cell type 2 (Th 2) and concomitantly inhibits Th 1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160–167.
   PubMed Web of Science ®Google Scholar
• Shannon EJ, Aseffa A, Pankey G, Sandoval F, Lutz B. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4 + cells in their blood. Immunopharmacology 2000;46: 175 — 179.
   Google Scholar
• Verbon A, Juffermans NP, Speelman Petal. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000;44:2286— 2290.
   Google Scholar
• Zwingenberger K, Wnendt S. Immunomodulation by thali-domide: systematic review of the literature and of unpublished observations. J Inflamm 1996;46:177 — 211.
   Google Scholar
• Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4 + and CD8 + T cells. Chin Exp Immunol 2002;130:75— 84.
   PubMed Web of Science ®Google Scholar
• Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20:538— 540.
   Google Scholar
• Karrow NA, McCay JA, Brown RD et al. Thalidomide stimulates splenic Ig,M antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation num-bers in female B6C3F1 mice. Toxicol Appl Pharmacol 2000;165:237 —244.
   PubMed Web of Science ®Google Scholar
• Di Fabio S, Trabattoni D, Geraci A et al. Study of immunological and virological parameters during thalidomide treatment of SW-infected cynomolgus monkeys. J Med Primatol 2000;29:1–10.
   PubMed Web of Science ®Google Scholar
• Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalido-mide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Leprosy Rev 1985;56:35–39.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210 — 216.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H et al. World Health Organization (WHO) international working group: report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671— 3674.
   PubMed Web of Science ®Google Scholar
• Santos-Mendoza T, Favila-Castillo L, Oltra A et al. Thalido-mide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allergy Immunol 1996;111:13–17.
   PubMed Web of Science ®Google Scholar
• Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000;181: 954–965.
   Google Scholar
• Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G. Thalidomide's effectiveness in erythema nodosum lepro-sum is associated with a decrease in CD4 + cells in peripheral blood. Leprosy Rev 2000;63: 5 —11.
   Google Scholar